🫀 2nd Year IMPACT Consortium Meeting | Milan, 2025
We are glad to share that the IMPACT EU project consortium gathered in Milan on 9–10 October 2025 for the 2nd Year Consortium Meeting!
The two-days event, kindly hosted by @Consorzio Italbiotec, was a great opportunity to bring together all partners of IMPACT to share results, review the progress achieved so far and align on upcoming activities in the study of arrhythmogenic cardiomyopathy (ACM).
💡 Discussions covered advances in data integration, predictive genetics and the generation of innovative preclinical and organoid models that shed new light on disease mechanisms. New findings on chemogenomic screening and HDAC inhibitors were also presented, alongside with AI-driven approaches supporting drug discovery and analysis.
💭Two round tables encouraged open dialogue and collaboration among partners: the first focused on omics data strategies and the second on exploitation and innovation management, setting shared directions for the next project phase.
🌍 The meeting further reinforced collaboration across the consortium, confirming the collective commitment that drives IMPACT in advancing knowledge and developing innovative therapeutic opportunities for patients with arrhythmogenic cardiomyopathy.
🙌🏻 A huge thank you to all partners for their commitment and inspiring contributions!
We look forward to continuing this exciting journey toward more precise and effective therapies for ACM!
Università degli Studi di Padova, Consorzio Italbiotec, Maastricht University, ITALFARMACO S.P.A., Lutech, Ksilink, UMC Utrecht, CoLAB AccelBio
